DE NICOLA, STELLA
DE NICOLA, STELLA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting
2021 M. Fabbiani, A. Lombardi, M. Colaneri, P. Del Poggio, P. Perini, R. D'Ambrosio, E. Degasperi, C. Dibenedetto, A. Giorgini, L. Pasulo, F. Maggiolo, F. Castelli, P. Brambilla, O. Spinelli, T. Re, A. Lleo, M. Rumi, C. Uberti-Foppa, A. Soria, A. Aghemo, P. Lampertico, C. Baiguera, M. Schiavini, S. Fagiuoli, R. Bruno, M. Borghi, R. Soffredini, R. Perbellini, A. Gori, V. Ferroni, M. Colpani, M. Manini, G. Cologni, S. Lazzaroni, M. Vinci, S. De Nicola, C. Mazzarelli, T. Angelini Zucchetti, V. Picciotto, M. Puoti, R. Rossotti, S. Landonio, C.F. Magni, G. Rizzardini, E. Colella, P. Columpsi, A. Gambaro, A. Spolti, C. Magnani, P. Vigano, M. Mena, M. Villa, I. Caramma, C. Basilico, F. Capelli, S. Biagiotti, A. Mazzone, V. Saladino, M.P. Baldacci, F. Gatti, L. Varalli, L. Morini, B. Menzaghi, M. Farinazzo, R. Meli, M.C. Plaz Torres, M. Rumi, I. Fanetti, C. Dibenedetto, D. Orellana, P. Zermiani, M. Zuin, A. De Bona, A. D'Arminio Monforte, A. Capretti, M.T. Taddei, M. Soncini, A. Spinetti, S. Zaltron, M.G. Pigozzi, A. Rossini, A. Pan, S. Dal Zoppo, A. Zoncada, M. Memoli, S. Salpietro, H. Hamid, E. Messina, A.E. Colombo, O. Giglio, P. Bonfanti, C. Molteni, N. Terreni, G. Spinzi, S. Conforti, E. Clerici, F. Menozzi, E. Buscarini, R. Centenaro, A. Corbellini, F. Noventa, S. Gritti, P. Giani
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
2018 E. Degasperi, A. Aghemo, S. Paolucci, R. D'Ambrosio, M. Borghi, R. Perbellini, F. Novazzi, S. De Nicola, G. Lunghi, F. Baldanti, P. Lampertico
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin
2016 E. Degasperi, S. DE NICOLA, M. Rumi, R. D'Ambrosio
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
2015 M. Milano, A. Aghemo, R.M. Mancina, J. Fischer, P. Dongiovanni, S. De Nicola, A.L. Fracanzani, R. D'Ambrosio, M. Maggioni, R. De Francesco, S. Fargion, T. Berg, F. Stickel, J. Hampe, S. Romeo, M. Colombo, L. Valenti
Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis
2014 S. De Nicola, A. Aghemo, M.R. Campise, R. D'Ambrosio, M.G. Rumi, P. Messa, M. Colombo
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent
2014 R. D'Ambrosio, A. Aghemo, R. De Francesco, M.G. Rumi, E. Galmozzi, S. De Nicola, C. Cheroni, P.J. Clark, G. Ronchi, P. Lampertico, M. Colombo
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C
2014 S. De Nicola, P. Dongiovanni, A. Aghemo, C. Cheroni, R. D'Ambrosio, M. Pedrazzini, F. Marabita, L. Donnici, M. Maggioni, S. Fargion, M. Colombo, R. De Francesco, L. Valenti
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients
2013 A. Aghemo, E. Degasperi, M.G. Rumi, E. Galmozzi, L. Valenti, R. De Francesco, S. De Nicola, C. Cheroni, E. Grassi, M. Colombo
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C
2012 A.M. Aghemo, G.M. Prati, M. Rumi, R.M. Soffredini, R. D'Ambrosio, E. Orsi, S. De Nicola, E. Degasperi, V. Grancini, M. Colombo
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis
2012 G.M. Prati, A.M. Aghemo, M. Rumi, R. D'Ambrosio, S. De Nicola, M.F. Donato, E. Degasperi, M. Colombo
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
2012 S. De Nicola, A. Aghemo, M. Rumi, E. Galmozzi, L. Valenti, R. Soffredini, R. De Francesco, G. Prati, R. D'Ambrosio, C. Cheroni, M.F. Donato, M. Colombo
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C
2011 L.V.C. Valenti, S. De Nicola, A. Staettermayer, A.M. Aghemo, P. Maggioni, B.M. Motta, P. Ferenci, M. Colombo, S.R. Fargion
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
2011 L.V.C. Valenti, M. Rumi, E. Galmozzi, A.M. Aghemo, B. Del Menico, S. De Nicola, P. Dongiovanni, M. Maggioni, A.L. Fracanzani, R. Rametta, M. Colombo, S.R. Fargion
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
2011 R. D'Ambrosio, A. Aghemo, M. Rumi, M. Primignani, A. Dell' Era, P. Lampertico, M. F. Donato, S. De Nicola, G. M. Prati, R. de Franchis, M. Colombo
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection
2011 F. Marabita, A.M. Aghemo, S. De Nicola, M. Rumi, C. Cheroni, R. Scavelli, M. Crimi, R.M. Soffredini, S. Abrignani, R. De Francesco, M. Colombo
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C
2010 L.V.C. Valenti, M.G. Rumi, E. Galmozzi, A.M. Aghemo, B. Del Menico, S. De Nicola, P. Dongiovanni, M. Maggioni, A.L. Fracanzani, R. Rametta, M. Colombo, S.R. Fargion
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C
2010 L.V.C. Valenti, M. Rumi, E. Galmozzi, A.M. Aghemo, B. Del Menico, S. De Nicola, P. Dongiovanni, M. Maggioni, A.L. Fracanzani, R. Rametta, M. Colombo, S.R. Fargion
Twelve-week post-treatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy
2010 A. Aghemo, M.G. Rumi, S. De Nicola, M. Colombo